CagriSema REDEFINE-2: superior weight loss in type 2 diabetes

Novo Nordisk has reported positive results from the REDEFINE-2 Phase 3 trial, in which CagriSema — a fixed-dose combination of cagrilintide (a long-acting amylin analog) and semaglutide (a GLP-1 receptor agonist) — demonstrated superior weight loss in adults with obesity or overweight and type 2 diabetes.

The REDEFINE programme

REDEFINE-2 is part of Novo Nordisk's broader REDEFINE Phase 3 programme for CagriSema. The previously reported REDEFINE-1 trial, focused on obesity without type 2 diabetes, showed 22.7% weight loss — among the highest reported for any anti-obesity pharmacotherapy. REDEFINE-2 extends these findings to the type 2 diabetes population, a group where weight management is clinically critical but often complicated by competing glycemic control priorities.

Why the amylin + GLP-1 combination matters

CagriSema represents a mechanistically distinct approach to the dual and triple agonists dominating the obesity pipeline. Rather than targeting multiple incretin receptors with a single molecule (as tirzepatide does with GIP/GLP-1, or retatrutide with GIP/GLP-1/glucagon), CagriSema combines two separate peptide hormones:

  • Cagrilintide — a long-acting amylin analog that suppresses glucagon, slows gastric emptying, and promotes satiety
  • Semaglutide — a GLP-1 receptor agonist with established efficacy in both type 2 diabetes and obesity

The rationale is that amylin and GLP-1 act through complementary pathways, potentially achieving greater weight loss than either agent alone without proportionally increasing adverse effects.

Implications for the competitive landscape

The REDEFINE-2 results position CagriSema as a serious competitor in the increasingly crowded obesity and type 2 diabetes market. Key comparisons include:

  • Tirzepatide (Mounjaro/Zepbound): dual GIP/GLP-1 agonist, already approved for both T2D and obesity
  • Retatrutide: triple GIP/GLP-1/glucagon agonist in Phase 3 (TRIUMPH programme)
  • Orforglipron: oral GLP-1 agonist, recently approved for obesity and showing positive Phase 3 T2D results

CagriSema's weight loss in the T2D population will be particularly scrutinised against tirzepatide's established SURPASS programme data, which showed significant weight loss alongside glycemic improvements in type 2 diabetes.

What researchers should watch for

The topline announcement confirms superiority for weight loss. Full results will be critical for assessing:

  • Magnitude of weight loss compared to semaglutide alone and cagrilintide alone
  • HbA1c reductions — glycemic control remains a primary endpoint in T2D
  • Safety profile, particularly gastrointestinal events and hypoglycaemia risk
  • Body composition changes — whether weight loss favours fat mass over lean mass
  • Cardiovascular and renal outcomes

UK context

CagriSema is not licensed in the UK. Semaglutide is available as Ozempic (T2D) and Wegovy (obesity/MASH) on the NHS, subject to NICE guidance and supply constraints. If CagriSema receives MHRA approval, NICE appraisal would be required for NHS access. The combination's efficacy in the T2D population could strengthen its case for reimbursement, given the high prevalence of obesity in UK T2D patients and the known benefits of weight loss for glycemic control.

Related compound profiles

Research use only

This article is for research and educational purposes only. CagriSema is an investigational combination product. It is not licensed as a research peptide for non-clinical use. Nothing in this article constitutes medical advice.

This article is AI-researched and editorially reviewed. It is provided for research and educational purposes only and is not medical advice. Research peptides are not licensed for human consumption in the UK.